Varenicline Tartrate Patent Expiration

1. Chantix patent expiration

CHANTIX IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6410550 PF PRISM CV Aryl fused azapolycyclic compounds
May, 2020

(4 years ago)

US6410550

(Pediatric)

PF PRISM CV Aryl fused azapolycyclic compounds
Nov, 2020

(3 years ago)

US6890927 PF PRISM CV Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
May, 2022

(2 years ago)

US7265119 PF PRISM CV Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
Aug, 2022

(1 year, 11 months ago)

US6890927

(Pediatric)

PF PRISM CV Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
Nov, 2022

(1 year, 8 months ago)

US7265119

(Pediatric)

PF PRISM CV Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
Feb, 2023

(1 year, 5 months ago)




Drug Exclusivity Drug Exclusivity Expiration
M(M-105) Jul 22, 2014
M(M-143) Oct 15, 2017
M(M-144) Oct 15, 2017
M(M-183) Aug 12, 2019
M(M-192) Dec 16, 2019
M(M-237) Feb 22, 2022
Pediatric Exclusivity(PED) Aug 22, 2022

Market Authorisation Date: 10 May, 2006

Treatment: Aid to smoking cessation

Dosage: TABLET

How can I launch a generic of CHANTIX before it's drug patent expiration?
More Information on Dosage

CHANTIX family patents

Family Patents

2. Tyrvaya patent expiration

TYRVAYA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9504645 OYSTER POINT PHARMA Pharmaceutical formulations for treating ocular conditions
Oct, 2035

(11 years from now)

US9532944 OYSTER POINT PHARMA Methods of improving ocular discomfort
Oct, 2035

(11 years from now)

US9597284 OYSTER POINT PHARMA Dry eye treatments
Oct, 2035

(11 years from now)

US10456396 OYSTER POINT PHARMA Dry eye treatments
Oct, 2035

(11 years from now)

US11224598 OYSTER POINT PHARMA Methods of increasing lacrimal proteins
Oct, 2035

(11 years from now)

US11903941 OYSTER POINT PHARMA Compositions and use of varenicline for treating dry eye
Oct, 2035

(11 years from now)

US11903943 OYSTER POINT PHARMA Compositions and use of varenicline for treating dry eye
Oct, 2035

(11 years from now)

US11903942 OYSTER POINT PHARMA Compositions and use of varenicline for treating dry eye
Oct, 2035

(11 years from now)

US11911380 OYSTER POINT PHARMA Compositions and use of varenicline for treating dry eye
Oct, 2035

(11 years from now)

US9504644 OYSTER POINT PHARMA Methods of increasing tear production
Oct, 2035

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 15, 2024

Market Authorisation Date: 15 October, 2021

Treatment: Treatment of the signs and symptoms of dry eye disease (ded)

Dosage: SPRAY

How can I launch a generic of TYRVAYA before it's drug patent expiration?
More Information on Dosage

TYRVAYA family patents

Family Patents